三生制药(SSRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SSRX 三生制药

休市中 11-22 16:00:00 EST

0.0000

+0.0000

--

最高0.0000	最低0.0000	成交量0.00
今开0.0000	昨收0.0000	日振幅0.00%
总市值0.00	流通市值0.00	总股本0.00
成交额0.00	换手率--	流通股本0.00
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"SSRX","market":"US","secType":"STK","nameCN":"三生制药","latestPrice":0,"timestamp":1732309200000,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","marketStatusCode":7,"change":0,"latestTime":"11-22 16:00:00 EST","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732525200000},"adr":0,"adjPreClose":0,"volumeRatio":0},"requestUrl":"/m/hq/s/SSRX","defaultTab":"news","newsList":[{"id":"2304574955","title":"《大行报告》富瑞下调三生制药(01530.HK)目标价至9元  评级“持有”","url":"https://stock-news.laohu8.com/highlight/detail?id=2304574955","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2304574955?lang=zh_cn&edition=full","pubTime":"2023-01-18 09:54","pubTimestamp":1674006840,"startTime":"0","endTime":"0","summary":"富瑞发表研究报告指，三生制药的核心产品特比澳获中国工信部审核，用于治疗在儿童或青少年的慢性原发性免疫性血小板减少症，数据显示产品三期临床研究已达到预设有效率主要终点，见效快并具良好安全性。考虑到公司的产品管线、市场竞争、合作、监管等因素，富瑞将三生制药目标价由10元降至9元，评级“持有”。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1239807/latest-news/HK6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01530","SSRX"],"gpt_icon":0},{"id":"2301728928","title":"《半日速报》恒指升210点; 恒生科技指数升47点 美团升逾3% 百威亚太、九毛九、中国中免、六福、三生制药创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2301728928","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2301728928?lang=zh_cn&edition=full","pubTime":"2023-01-05 12:12","pubTimestamp":1672891920,"startTime":"0","endTime":"0","summary":"恒指半日收21,003点，升210点或1.0%。恒生科技指数报4,474点，升47点或1.1%。国指升84点或1.2%，报7,150点。沽空资料截至 2023-01-04 16:25。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190213170708072_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190213170708072_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1236800/latest-news/HK6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1142","QNETCN","LU0456846285.SGD","LU0456827905.SGD","LU0823040885.USD","BK1224","LU0348805143.USD","LU0072913022.USD","LU0320764599.SGD","LU0417516902.SGD","LU1720050803.USD","LU0878005551.USD","LU0326950275.SGD","LU0128522157.USD","LU0348814723.USD","LU0359201612.USD","LU1242518931.SGD","HSI","LU1328615791.USD","LU1807302812.USD","BK1233","HHImain","BK1591","LU0320764755.SGD","LU0051755006.USD","513600","01880","LU0577902371.SGD","LU0577902298.EUR","BK1521","01530","90013","LU0431992006.USD","LU1688375341.USD","LU0052750758.USD","LU0577902538.SGD","LU0417516738.SGD","LU1023057109.AUD","LU0708995583.HKD","LU0918141887.USD","BK1593","LU0348825331.USD","LU0543330483.HKD","BK1589","LU1794554557.SGD","09922","MCHmain","LU0873338254.USD","SSRX","LU0348735423.USD"],"gpt_icon":0},{"id":"2295908023","title":"三生制药(01530)委任张丹为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2295908023","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2295908023?lang=zh_cn&edition=full","pubTime":"2022-12-30 20:12","pubTimestamp":1672402326,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，唐柯先生辞任公司非执行董事及薪酬委员会成员，自2022年12月30日起生效。此外，张丹博士已获委任为公司独立非执行董事及薪酬委员会成员，自2022年12月30日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/855494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","BK1161","BK1583","BK1593","SSRX"],"gpt_icon":0},{"id":"2285883323","title":"【港股通】三生制药(01530)涨逾4% 大摩料其今年销售增长目标升至双位数","url":"https://stock-news.laohu8.com/highlight/detail?id=2285883323","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2285883323?lang=zh_cn&edition=full","pubTime":"2022-11-22 14:58","pubTimestamp":1669100296,"startTime":"0","endTime":"0","summary":"三生制药(01530)盘中走强，午后维持高位，最新报7.7港元，涨4.05%，成交额1.58亿港元。大摩发研报指，由于在疫情下内地药品集中采购实施日期进一步推迟等，预期三生制药今年的销售增长目标会由10%以下，调升至双位数；至于盈利因汇兑收益影响，估计会增长20%至30%。该行将三生制药目标价由6.2港元升21%至7.5港元，评级维持“与大市同步”，并调升集团今年至2024年销售预测分别5%、6%及7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=a4c4deed12bd620629bc4945d5f50524","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772840.SGD","BK1583","BK4534","LU1074936037.SGD","LU1668664300.SGD","MS","01530","BK1593","BK4504","LU0106831901.USD","BK4581","LU1363072403.SGD","BK4127","BK1161","LU0971096721.USD","BK4585","LU1989772923.USD","SSRX"],"gpt_icon":0},{"id":"2285500763","title":"港股异动 | 三生制药(01530)续涨5%、本月累升40% 大摩上调销售预测及目标价 特比澳新增上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2285500763","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2285500763?lang=zh_cn&edition=full","pubTime":"2022-11-22 11:39","pubTimestamp":1669088366,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药持续活跃，早盘最高触及7.85港元，月内，股价累升约40%。大摩最新表示，预计公司将上调销售增长目标。近日，核心产品特比澳新上市申请获受理，用于治疗儿童ITP。截至发稿，三生制药涨4.19%，报7.71港元，成交额1.03亿港元。日前，摩根士丹利发布更新报告称，预计三生制药今年的销售增长目标调升至双位数，盈利预测增长20%至30%。大摩上调公司目标价，由6.2港元升至7.5港元，并调升公司22年-24年销售预测分别5%、6%及7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/835202.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SSRX","01530"],"gpt_icon":0},{"id":"2285006259","title":"*大摩上调三生制药(01530.HK)目标价至7.5元  评级「与大市同步」","url":"https://stock-news.laohu8.com/highlight/detail?id=2285006259","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2285006259?lang=zh_cn&edition=full","pubTime":"2022-11-22 10:15","pubTimestamp":1669083319,"startTime":"0","endTime":"0","summary":"~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1228058&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["01530","SSRX"],"gpt_icon":0},{"id":"2285333015","title":"港股异动 | 三生制药(01530)升8% 特比澳儿童ITP适应症申报上市 国信维持“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2285333015","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2285333015?lang=zh_cn&edition=full","pubTime":"2022-11-21 11:22","pubTimestamp":1669000954,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药再度显著走强，早盘升约8%。近日，公司核心产品特比澳新上市申请获NMPA受理，用于治疗儿童或青少年ITP。截至发稿，三生制药涨8.29%，报7.45港元，成交额0.93亿港元。今年上半年，特比澳实现销售15.75亿元，在公司收入中占比约51%。公司盈利能力强，现金流充沛，维持“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/834356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","BK1161","BK1583","BK4199","BK1593","ITP","SSRX"],"gpt_icon":0},{"id":"2282575061","title":"港股异动 | 三生制药(01530)升6% 特比澳新增儿童ITP适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2282575061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2282575061?lang=zh_cn&edition=full","pubTime":"2022-11-10 14:28","pubTimestamp":1668061688,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药再度活跃，午后升约6%。截至发稿，三生制药涨5.65%，报6.73港元，成交额1.52亿港元。11月9日，三生制药宣布，公司向NMPA提交的重组人血小板生成素注射液（特比澳）新上市申请已于日前获得受理，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症。特比澳作为三生制药自主研发的全球唯一商业化的重组人血小板生成素产品，2005年产品成功上市。今年上半年，特比澳实现销售15.75亿元，在公司收入中占比达50.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/827905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4199","BK1161","01530","ITP","BK1593","SSRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"沈阳三生制药有限责任公司成立于1993年，是集生物药品的研发、生产和销售一体化的高新技术企业。公司开发重组或基因工程蛋白类药物，以满足临床治疗肾脏病、肿瘤、肿瘤支持治疗、以及其他炎症和传染类疾病的市场需求。","exchange":"NASDAQ","name":"三生制药","nameEN":"三生制药"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(SSRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(SSRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,SSRX,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(SSRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(SSRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}